All News Portage Biotech Inc.

Equities

PRTG

VGG7185A1286

Market Closed - Nasdaq Other stock markets 04:30:00 2024-04-25 pm EDT			5-day change	1st Jan Change
0.237 ^USD	-5.28%		-1.25%	-86.98%

Apr. 15	Portage Biotech Announces Plans to Expand Its Evaluation of Strategic Alternatives	CI
Apr. 12	Portage Biotech Announces Plans to Expand Its Evaluation of Strategic Alternatives	CI

All News

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Portage Biotech Announces Plans to Expand its Evaluation of Strategic Alternatives-Adenosine clinical development paused	Apr. 15	AQ
Portage biotech announces plans to expand its evaluation of strategic alternatives	Apr. 15	AQ
Portage Biotech Announces Plans to Expand Its Evaluation of Strategic Alternatives	Apr. 15	CI
Portage Biotech Announces Plans to Expand its Evaluation of Strategic Alternatives	Apr. 12	AQ
Portage Biotech Announces Plans to Expand Its Evaluation of Strategic Alternatives	Apr. 12	CI
Portage biotech completes monetization of intensity therapeutics shares	Mar. 27	AQ
Portage Biotech Completes Monetization of Intensity Therapeutics (INTS) shares	Mar. 26	AQ
Portage Biotech : Corporate Presentation - March 2024	Mar. 07	PU
Portage Biotech Reports Results for Fiscal Quarter Ended December 31, 2023, and Business Update	Feb. 28	AQ
Portage Biotech Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	Feb. 28	CI
HC Wainwright Downgrades Portage Biotech to Neutral From Buy	Jan. 08	MT
Portage Biotech to Pause Drug Development in PORT-2 iNKT Program, to Cut Workforce	Jan. 04	MT
Portage Biotech to Evaluate Range of Strategic Options	Jan. 04	CI
Portage Biotech Reports Business and Strategic Update	Jan. 04	AQ
Portage Biotech Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	Nov. 28	CI
Portage Biotech Reports Results for Fiscal Quarter Ended June 30, 2023, and Business Update	Nov. 28	AQ
Portage biotech presents updates on its inkt and adenosine programs at the society for immunotherapy of cancer's 38th annual meeting	Nov. 07	AQ
Portage Biotech Presents Updates on its iNKT and Adenosine programs at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting	Nov. 06	AQ
Portage Biotech Inc. Presents Updates on its iNKT and Adenosine Programs at the Society for Immunotherapy of Cancer's 38th Annual Meeting	Nov. 06	CI
Portage Biotech Inc. announced that it has received $5.3 million in funding	23-10-02	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

All News Portage Biotech Inc.

Equities

PRTG

VGG7185A1286

All News

Filters